Relmada Therapeutics Inc. (NASDAQ: RLMD)
$3.79
-0.0500 ( -1.30% ) 63.9K
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Market Data
Open
$3.79
Previous close
$3.84
Volume
63.9K
Market cap
$113.76M
Day range
$3.76 - $3.89
52 week range
$2.42 - $7.22
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Dec 19, 2023 |
4 | Insider transactions | 1 | Dec 19, 2023 |
4 | Insider transactions | 1 | Dec 19, 2023 |
4 | Insider transactions | 1 | Dec 19, 2023 |
4 | Insider transactions | 1 | Dec 19, 2023 |
10-q | Quarterly Reports | 47 | Nov 08, 2023 |
8-k | 8K-related | 14 | Nov 08, 2023 |
8-k | 8K-related | 14 | Oct 11, 2023 |
8-k | 8K-related | 49 | Oct 10, 2023 |
8-k | 8K-related | 49 | Oct 04, 2023 |